Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 28, 2026
TickeronGET DAILY SIGNALS
Heron Therapeutics (HRTX): Evaluating the Feasibility of a Return to $1.00

Heron Therapeutics (HRTX): Evaluating the Feasibility of a Return to $1.00

Key Takeaways

  • The central objective examined here is $1.00, which is not an analyst consensus; it is drawn from public discussion of the Nasdaq $1.00 minimum-bid requirement and the stock's prior support zone.
  • With the latest verified price near $0.30, reaching $1.00 would require a roughly 230% advance, a very large move.
  • There is no current, maintained analyst price target. H.C. Wainwright removed its last $2 target in August 2026 when it downgraded the stock to Neutral, and Needham moved to Hold without a target in June 2026.
  • The strongest support for a recovery is growth in the acute-care franchise (ZYNRELEF and APONVIE) and the company's moves to cut spending and explore strategic alternatives.
  • The biggest risk is generic competition for CINVANTI, which accounts for about 60% of product sales, after a June 2026 court ruling.
  • Investors can find more on this ticker's Major News, Today's Price Move, Forecast, and Earnings.
  • For automated, AI-driven trade ideas across thousands of stocks and ETFs, explore Trending AI Robots.

Where the $1.00 Level Originates

Because HRTX no longer has a meaningful set of current, maintained analyst price targets, a conventional consensus cannot be constructed. H.C. Wainwright's Brandon Folkes trimmed the target from $6 to $4, then to $2, before removing it entirely in August 2026 while downgrading the stock to Neutral. Needham's Serge Belanger moved to Hold with no target in June 2026. An earlier Jefferies target of $5 dates to November 2025 and is stale. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The $1.00 objective therefore comes from public discussion rather than analyst research. It reflects the $1.00 Nasdaq minimum-bid threshold for continued listing and a round-number psychological level that also matches the stock's early-2026 support area near $1.04 to $1.17. It should be read as a recovery milestone, not a valuation-based target.

Current Position and the Scale of the Required Move

Heron Therapeutics shares closed near $0.30 on October 27, 2026, with a market capitalization of roughly $57 million and a 52-week range of $0.26 to $1.58. Reaching $1.00 implies an advance of about 230%, a very large move by any standard. A reversal of that size would likely require clarity that CINVANTI's revenue can withstand generic entry, continued double-digit growth in the acute-care products, and progress toward a sustainable balance sheet, since the company is evaluating strategic alternatives.

Factors That Could Support Recovery

The acute-care business is the clearest positive. In Q1 2026, acute-care net revenue grew 32% year over year, driven by ZYNRELEF and APONVIE, and Q2 revenue rose to about $37.7 million. Heron also signed a multi-product development and license agreement with Long Grove Pharmaceuticals and Capstone in September 2026, which could add optionality. Aggressive cost controls and a possible Federal Circuit appeal of the CINVANTI patent decision could also help sentiment. A favorable resolution, or a strategic transaction, would be the most direct catalyst for a repricing. From what I see, these elements form the most credible foundation for any stabilization.

Risks That Could Block the Target

The June 2026 Delaware court ruling invalidating certain CINVANTI patent claims opened the door to final FDA approval and commercial launch of a generic by Azurity and Sandoz. Because CINVANTI represents roughly 60% of product sales, rapid generic erosion would pressure revenue and covenants. The company has withdrawn its 2026 guidance, carries elevated debt relative to equity, and ended the second quarter with about $42.7 million in cash. Delisting risk from the sub-$1 share price and possible shareholder dilution from any financing or reverse split also weigh on the path to $1.00. This is important because those pressures could outweigh the acute-care gains in the near term.

Technical Levels and Market Structure

The stock's 52-week low near $0.26 sits just below the current price, meaning there is little historical support beneath the market. On the upside, $1.00 is both the Nasdaq minimum-bid threshold and a major psychological level, reinforced by the $1.04-to-$1.17 band that acted as support early in 2026. The 52-week high near $1.58 marks a far more distant reference point. The long-term structure remains in a downtrend until the stock can reclaim and hold a level decisively above $1.00.

Time Horizon and Metrics to Watch

Analyst targets are typically framed around a 12-month horizon, but with no maintained target on the stock, there is no official research timeframe to rely on here. The most important near-term event is the third-quarter report scheduled for November 9, 2026, where investors will watch CINVANTI sales trends, cash burn, covenant compliance, and any update on strategic alternatives. The progress of the patent appeal and any FDA generic-approval actions are equally significant. I’m watching this closely ahead of the earnings release.

Leveraging AI Tools in Analysis

When reviewing fast-moving names like this one, I frequently turn to Tickeron's AI Daily Buy/Sell Signals. The tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. It allows traders to surface new opportunities, track existing positions, and spot changing trends more efficiently than manual screening, which is especially useful for a stock where technicals and news flow can shift quickly.

Final Assessment

The question of whether Heron Therapeutics can reach $1.00 hinges on a recovery of roughly 230% from current levels, a very large move that is not supported by any maintained analyst target. The acute-care portfolio's growth and the company's cost discipline provide a genuine foundation for stabilization, but CINVANTI's generic exposure, withdrawn guidance, a stretched balance sheet, and listing-compliance risk are formidable obstacles. With no active analyst coverage anchoring valuation, the $1.00 level functions best as a milestone for monitoring execution, the patent appeal, and any strategic outcome rather than as a forecast.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: HRTX

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


HRTX's Stochastic Oscillator is staying in oversold zone for 1 day

Be on the lookout for a price bounce soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +27.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where HRTX advanced for three days, in 181 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HRTX as a result. In 69 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

The Moving Average Convergence Divergence Histogram (MACD) for HRTX turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 37 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

HRTX moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for HRTX crossed bearishly below the 50-day moving average on October 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

HRTX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for HRTX entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.496) is normal, around the industry mean (3.592). P/E Ratio (-1.542) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.387) is also within normal values, averaging (442.120).

The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. HRTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HRTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -11%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -24%. SLS experienced the highest price growth at 129%, while CUE experienced the biggest fall at -85%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 8%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was -15%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of polymer technologies

Industry Biotechnology

Industry
Biotechnology
Address
100 Regency Forect Drive
Phone
+1 858 251-4400
Employees
128
Web
https://www.herontx.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.